Fulgent Oncology

Fulgent Oncology We're a national cancer reference laboratory that prioritizes patient care and diagnostic accuracy through advanced technology.

As a brand under Fulgent Genetics, Fulgent Oncology provides personalized cancer diagnostics services through CSI Laboratories and Inform Diagnostics, Fulgent Genetics subsidiaries. Together, our labs have helped pathologists and oncologists accurately diagnose and treat their patients for over 25 years. Our in-house medical team works closely with pathologists, oncologists and technicians to prov

ide comprehensive diagnostic testing and analysis throughout the United States and Caribbean. We invest in an expert medical team, the right technology and equipment, and training to provide a higher level of service to customers. Our testing services include: Flow Cytometry, FISH, Cytogenetic Analysis, Histology and Molecular Genetics. We also provide hematopathology and surgical pathology consultations and second opinions to support diagnosis and treatment decisions. We understand the need to deliver accurate and fast test results and we are driven every day by our mission to provide personalized cancer diagnostics to support pathologists in providing care to cancer patients.

04/25/2026

The 1970's marked an increase in clinical lab usage that parallelled a shortage of lab technicians, which has remained an unfortunate trend to this day. In 2020, that shortage was keenly felt as the COVID pandemic caused a surge in lab testing. Lab workers are the all-too-often unsung heroes of healthcare.

So this , we'd like to express our gratitude to the Fulgent lab staff who work tirelessly behind the scenes on behalf of patients and the healthcare community. Thank you for all you do.

04/22/2026

The latest findings on the efficacy of Fulgent's nano-encapsulated anti-tumor drug FID-007 will be presented at this year's American Society of Clinical Oncology (ASCO) meeting.

We're proud to announce that our abstract, “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)”, will be featured at the Head and Neck Cancer Track of the ASCO rapid oral abstract session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in hall D1 of McCormick Place, Chicago.

The Phase 2 study is designed to evaluate the efficacy of different dosing regimens as well as to characterize the pharmacokinetics (PK) and safety and tolerability of FID-007 in combination with cetuximab in patients with disease progression after treatment with PD-L1-based immune checkpoint inhibitor.

https://www.businesswire.com/news/home/20260422182838/en/Fulgent-Selected-to-Present-Rapid-Oral-Abstract-Within-the-Head-and-Neck-Cancer-Track-Session-at-the-2026-ASCO-Annual-Meeting

Excited to share that we’ll be attending from April 28-29 in Orlando! Drop by booth 816, where our team will have inf...
04/22/2026

Excited to share that we’ll be attending from April 28-29 in Orlando!

Drop by booth 816, where our team will have info about Lumera - our NGS services offering industry-leading turnaround times for Liquid Biopsy, Solid Tumor, and Heme Malignancies.

We'd also love to tell you about Flow Cytometry Lab Partnership opportunities. Bring your Flow lab processes in-house for faster turnaround and greater continuity of care.

We look forward to exploring the future of cancer diagnostics with you!

We’re in San Antonio for ! Say hi to our team at booth 554. We’d love to discuss how Fulgent Oncology can support your ...
03/23/2026

We’re in San Antonio for ! Say hi to our team at booth 554. We’d love to discuss how Fulgent Oncology can support your pathology needs.

We’re heading out to San Antonio Mar 23 - Mar 25 for . Join us at booth 554 as we explore the latest developments in pa...
03/17/2026

We’re heading out to San Antonio Mar 23 - Mar 25 for . Join us at booth 554 as we explore the latest developments in pathology. Our team looks forward to connecting with colleagues both old and new!

Variants in the DPYD gene can create serious side-effects for patients taking fluorouracil or capecitabine. Fulgent Onco...
12/15/2025

Variants in the DPYD gene can create serious side-effects for patients taking fluorouracil or capecitabine. Fulgent Oncology’s PGx panel covers all DPYD variants with clinical guidelines from CPIC. Build safer, more personalized medications plans for your patients by ordering a PGx test.

Visit our Fulgent Oncology website to learn more: https://fulgentoncology.com/pgx

The DPYD gene is recommended for PGx testing by the FDA for certain chemotherapy drugs. Our Oncology PGx panel covers DP...
12/08/2025

The DPYD gene is recommended for PGx testing by the FDA for certain chemotherapy drugs. Our Oncology PGx panel covers DPYD variants with established guidelines by CPIC. These guidelines included dosing information for fluorouracil and capecitabine.

Visit our website to learn more about our PGx panel and build personalized medication plans for your patients.
https://fulgentoncology.com/pgx

Create a medication plan tailored to every patient’s unique needs with help from our PGx Oncology panel. This panel incl...
12/01/2025

Create a medication plan tailored to every patient’s unique needs with help from our PGx Oncology panel. This panel includes actionable and informative oncology-related genes as designated by the FDA and CPIC with results covering reactions associated with more than 15 oncology medications. You can also build a more holistic plan with our full PGx menu, which covers specialty areas beyond Oncology.

Visit our website for more info: https://fulgentoncology.com/pgx

Heading to the American Society for Clinical Pathology (ASCP) Annual Meeting, November 17–20?Stop by booth 218 to meet o...
11/12/2025

Heading to the American Society for Clinical Pathology (ASCP) Annual Meeting, November 17–20?
Stop by booth 218 to meet our team and discover how Fulgent Oncology is improving outcomes in cancer care—one patient at a time. See you in Atlanta!

We’re thrilled to welcome Dr. Michelle Shiller, DO, AP, CP, MGP, MSPT to the Fulgent Oncology team as our new Director o...
10/29/2025

We’re thrilled to welcome Dr. Michelle Shiller, DO, AP, CP, MGP, MSPT to the Fulgent Oncology team as our new Director of Medical Pathology!

Dr. Shiller is a distinguished global expert and key opinion leader in molecular pathology and precision oncology, bringing a wealth of clinical experience coupled with extensive educational efforts and molecular diagnostics practice. She has presented at global and national meetings including at the WCLC, European Congress for Pathology, and the United States and Canadian Association for Pathology. With her passion for driving education, growth, and the establishment of multidisciplinary dialogue, she has also led educational efforts with Baylor University Medical Center, the Cancer Research Symposium, and the Texas Society of Genetic Counselors.

We’re excited to have her on board as we continue shaping the future of oncology together.

On International Women's Day, we're celebrating the incredible achievements and contributions of women who are making a ...
03/08/2024

On International Women's Day, we're celebrating the incredible achievements and contributions of women who are making a difference in the field of cancer diagnostics. We're proud to be , with more than half of our medical team comprised of accomplished woman pathologists.

Address

Atlanta, GA

Telephone

+16782488000

Website

Alerts

Be the first to know and let us send you an email when Fulgent Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Fulgent Oncology:

Shortcuts

Share

Category